REFERENCES
1. Trenor, C.C., 3rd and G. Chaudry, Complex lymphatic anomalies.Semin Pediatr Surg, 2014. 23 (4): p. 186-90.
2. Lala, S., et al., Gorham-Stout disease and generalized
lymphatic anomaly–clinical, radiologic, and histologic
differentiation. Skeletal Radiol, 2013. 42 (7): p. 917-24.
3. de Villiers, J.F. and W.R. Stevens, Case 203: Gorham disease.Radiology, 2014. 270 (3): p. 931-5.
4. North, P.E., Pediatric Vascular Tumors and Malformations. Surg
Pathol Clin, 2010. 3 (3): p. 455-94.
5. Ozeki, M., et al., Clinical Features and Prognosis of
Generalized Lymphatic Anomaly, Kaposiform Lymphangiomatosis, and
Gorham-Stout Disease. Pediatr Blood Cancer, 2016. 63 (5): p.
832-8.
6. Rodriguez-Laguna, L., et al., Somatic activating mutations in
PIK3CA cause generalized lymphatic anomaly. J Exp Med, 2019.216 (2): p. 407-418.
7. Croteau, S.E., et al., Kaposiform lymphangiomatosis: a distinct
aggressive lymphatic anomaly. J Pediatr, 2014. 164 (2): p.
383-8.
8. Adams, D.M. and K.W. Ricci, Vascular Anomalies: Diagnosis of
Complicated Anomalies and New Medical Treatment Options. Hematol Oncol
Clin North Am, 2019. 33 (3): p. 455-470.
9. Ji, Y., et al., Kaposiform lymphangiomatosis and kaposiform
hemangioendothelioma: similarities and differences. Orphanet J Rare
Dis, 2019. 14 (1): p. 165.
10. Barclay, S.F., et al., A somatic activating NRAS variant
associated with kaposiform lymphangiomatosis. Genet Med, 2019.21 (7): p. 1517-1524.
11. Krishnamurthy, R., et al., Imaging the central conducting
lymphatics: initial experience with dynamic MR lymphangiography.Radiology, 2015. 274 (3): p. 871-8.
12. Dori, Y., M.M. Zviman, and M. Itkin, Dynamic contrast-enhanced
MR lymphangiography: feasibility study in swine. Radiology, 2014.273 (2): p. 410-6.
13. Li, D., et al., Pathogenic variant in EPHB4 results in central
conducting lymphatic anomaly. Hum Mol Genet, 2018. 27 (18): p.
3233-3245.
14. Iacobas, I., et al., Multidisciplinary guidelines for initial
evaluation of complicated lymphatic anomalies-expert opinion consensus.Pediatr Blood Cancer, 2020. 67 (1): p. e28036.
15. Alomari, M.C., R; Kerr, Cindy; O’Hare, M; Padua, H; Chaudry, G;
Chewning R; Alomari, A, Chylothorax Following Rib Biopsy in
Generalized Lymphatic Anomaly in 22nd International Workshop of
the International Society for the Study of Vascular Anomalies . 2018:
Amsterdam, Netherlands.
16. Adams, D.M., et al., Vascular anomaly cases for the pediatric
hematologist oncologists-An interdisciplinary review. Pediatr Blood
Cancer, 2018. 65 (1).
17. Simon, F., et al., Management of Gorham Stout disease with
skull-base defects: Case series of six children and literature review.Int J Pediatr Otorhinolaryngol, 2019. 124 : p. 152-156.
18. Evans, D.A., et al., Lymphangiomatosis of Skull Manifesting
with Recurrent Meningitis and Cerebrospinal Fluid Otorrhea.Otolaryngology–Head and Neck Surgery, 1990. 103 (4): p.
642-646.
19. Nazarian, G.K., S.S. Gebarski, and J.K. Niparko, Cranial
lymphangiomatosis causing CSF otorrhea and recurrent meningitis: CT
features. J Comput Assist Tomogr, 1990. 14 (1): p. 121-3.
20. Venkatramani, R., et al., Gorham’s disease and diffuse
lymphangiomatosis in children and adolescents. Pediatr Blood Cancer,
2011. 56 (4): p. 667-70.
21. Cramer, S.L., et al., Gorham-Stout Disease Successfully
Treated With Sirolimus and Zoledronic Acid Therapy. J Pediatr Hematol
Oncol, 2016. 38 (3): p. e129-32.
22. Ricci, K.W., et al., Efficacy of systemic sirolimus in the
treatment of generalized lymphatic anomaly and Gorham-Stout disease.Pediatr Blood Cancer, 2019. 66 (5): p. e27614.
23. Alvarez, O.A., I. Kjellin, and C.W. Zuppan, Thoracic
lymphangiomatosis in a child. J Pediatr Hematol Oncol, 2004.26 (2): p. 136-41.
24. Goyal, P., et al., Imaging features of kaposiform
lymphangiomatosis. Pediatr Radiol, 2016. 46 (9): p. 1282-90.
25. Fernandes, V.M., et al., Kaposiform lymphangiomatosis:
unifying features of a heterogeneous disorder. Pediatr Blood Cancer,
2015. 62 (5): p. 901-4.
26. Hammill, A.M., et al., Sirolimus for the treatment of
complicated vascular anomalies in children. Pediatr Blood Cancer, 2011.57 (6): p. 1018-24.
27. Adams, D.M., Special considerations in vascular anomalies:
hematologic management. Clin Plast Surg, 2011. 38 (1): p.
153-60.
28. Mizuno, T., et al., Developmental pharmacokinetics of
sirolimus: Implications for precision dosing in neonates and infants
with complicated vascular anomalies. Pediatr Blood Cancer, 2017.64 (8).